a References 213 19. Voakes JB, Jones SE, McKelvey EM (1981) The chemotherapy of lymphoblastic lymphoma. Blood 57:186–188 20. Liang R, Todd D, Chan TK, et al. (1991) Intensive chemotherapy for adult lymphoblastic lymphomas. Cancer Chemother Pharmacol 29:80–82 21. Kaiser U, Uebelacker I, Havemann K (1999) Non-Hodgkin’s lymphoma protocols in the treatment of patients with Burkitt’s lymphoma and lymphoblastic lymphoma: A report on 58 patients. Leuk Lymphoma 36:101–108 22. Coleman CN, Cohen JR, Burke JS, Rosenberg SA (1981) Lymphoblastic lymphoma in adults: Results of a pilot protocol. Blood 57:679–684 23. Coleman CN, Picozzi VJ Jr, Cox RS, et al. (1986) Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 4:1628–1637 24. Colgan JP, Andersen J, Habermann TM, et al. (1994) Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin’s lymphoma. Leuk Lymphoma 15:291–296 25. Chen YC, Ho CL, Kao WY, et al. (2001) Adult lymphoblastic lymphoma in Taiwan: An analysis of treatment results of 26 patients. Ann Hematol 80:647–652 26. Levine AM, Forman SJ, Meyer PR, et al. (1983) Successful therapy of convoluted T-lymphoblastic lymphoma in the adult. Blood 61:92–98 27. Santini G, Congiu A, D’Amico T, et al. (1989) Lymphoblastic lymphoma (LBL) and acute lymphoblastic leukaemia (ALL) in adults: Relationships and therapeutic perspectives. Bone Marrow Transplant 4(Suppl)1:106–107 28. Jabbour E, Koscielny S, Sebban C, et al. (2006) High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia 20:814–819 29. Hoelzer D, Gökbuget N (2002) Treatment of lymphoblastic lymphoma in adults. Best Pract Res Clin Haematol 15:713–728 30. Slater DE, Mertelsmann R, Koziner B, et al. (1986) Lymphoblastic lymphoma in adults. J Clin Oncol 4:57–67 31. Daenen S, van Imhoff GW, Haaxma-Reiche H, et al. (1995) <strong>Acute</strong> lymphoblastic leukemia: Single center experience with modified chemotherapy. Blood 86(S1):754a 32. Thomas DA, Cortes J, O’Brien S, et al. (1999) Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. J Clin Oncol 17:2461–2470 33. Daenen S, van Imhoff GW, Haaxma-Reiche H, et al. (1995) Outcome of a hybrid chemotherapy regimen with mediastinal irradiation in leukemic T-lymphoblastic lymphoma. Blood 86:754a 34. Song K, Barnett M, Gascoyne R, et al. (2007) Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes. Ann Oncol 18:535–540 35. Salloum E, Henry-Amar M, Caillou B, et al. (1988) Lymphoblastic lymphoma in adults: A clinicopathological study of 34 cases treated at the Institut Gustave-Roussy. Eur J Cancer Clin Oncol 24:1609–1616 36. Yeh KH, Cheng AL, Su IJ, et al. (1997) Prognostic significance of immunophenotypes in adult lymphoblastic lymphomas. Anticancer Res 17:2269–2272 37. Shepherd SF, A‘Hern RP, Pinkerton CR (1995) Childhood T-cell lymphoblastic lymphoma7Does early resolution of mediastinal mass predict for final outcome? The United Kingdom Children’s Cancer Study Group (UKCCSG). Br J Cancer 72:752–756 38. Spaepen K, Stroobants S, Dupont P, et al. (2001) Prognostic value of positron emission tomography (PET) with fluorine-18fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non- Hodgkin’s lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414–419 39. Mott MG, Eden OB, Palmer MK (1984) Adjuvant low dose radiation in childhood non-Hodgkin’s lymphoma (report from the United Kingdom Childrens‘ Cancer Study Group–UKCCSG). Br J Cancer 50:463–469 40. Camitta BM, Lauer SJ, Casper JT, et al. (1985) Effectiveness of a sixdrug regimen (APO) without local irradiation for treatment of mediastinal lymphoblastic lymphoma in children. Cancer 56: 738–741 41. Weinstein HJ, Cassady JR, Levey R (1983) Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol 1:537–541 42. Jost LM, Jacky E, Dommann-Scherrer C, et al. (1995) Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt’s lymphomas in adult patients. Ann Oncol 6:445–451 43. Mazza P, Bertini M, Macchi S, et al. (1986) Lymphoblastic lymphoma in adolescents and adults. Clinical, pathological and prognostic evaluation. Eur J Cancer Clin Oncol 22:1503–1510 44. Ferrando AA, Neuberg DS, Staunton J, et al. (2002) Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1:75–87 45. Milpied N, Ifrah N, Kuentz M, et al. (1989) Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission. Br J Haematol 73:82–87 46. Baro J, Richard C, Sierra J, et al. (1992) Autologous bone marrow transplantation in 22 adult patients with lymphoblastic lymphoma responsive to conventional dose chemotherapy. Bone Marrow Transplant 10:33–38 47. Verdonck LF, Dekker AW, de Gast GC, Lokhorst HM, Nieuwenhuis HK (1992) Autologous bone marrow transplantation for adult poor-risk lymphoblastic lymphoma in first remission. J Clin Oncol 10:644–646 48. Sweetenham JW, Liberti G, Pearce R, et al. (1994) High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: Results of the European Group for Bone Marrow Transplantation. J Clin Oncol 12:1358–1365 49. Conde E, Zuazu J, Lopez-Guillermo A, et al. (1999) Autologous stem cell transplantation (ASCT) for lymphoblastic lymphoma (LBL). Blood 94:2130a 50. Sweetenham JW, Santini G, Qian W, et al. (2001) High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: Results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 19:2927–2936 51. van Besien KW, Mehra RC, Giralt SA, et al. (1996) Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, toxicity and survival depend on disease histology. Am J Med 100:299–307
214 Chapter 16 · Treatment of Lymphoblastic Lymphoma in Adults 52. van Imhoff GW, van der HB, MacKenzie MA, et al. (2005) Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia 19:945–952 53. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. (1997) Allogeneic transplantation for lymphoma produces a lower relapse rate than autologous transplantation but survival is worse because of higher treatment related mortality7A report of 764 cases from the EBMT lymphoma registry. Blood 90:1121a 54. Levine JE, Harris RE, Loberiza FR Jr, et al. (2003) A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 101:2476–2482 55. van Besien K, Przepiorka D, Mehra R, et al. (1996) Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. J Clin Oncol 14: 3036–3042 56. Amylon MD, Shuster J, Pullen J, et al. (1999) Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study. Leukemia 13:335–342 57. Schrappe M, Reiter A, Ludwig WD, et al. (2000) Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL- BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 95:3310–3322 58. Bassan R, Pogliani E, Lerede T, et al. (1999) Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: First results from a phase II clinical study. Haematologica 84:1088–1093 59. Deangelo DJ, Yu D, Johnson JL, et al. (2007) Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and leukemia group B study 19801. Blood Mar 7 [Epub ahead of print]
- Page 1 and 2:
E.H. Estey · S.H. Faderl · H. M.
- Page 3 and 4:
E. H. Estey Department of Leukemia
- Page 5 and 6:
VI Table of Contents 14 Philadelphi
- Page 7 and 8:
VIII Contributors S. H. Faderl Depa
- Page 9 and 10:
X Contributors D. Wartenberg Depart
- Page 11 and 12:
Therapy of AML Elihu Estey Contents
- Page 13 and 14:
a 1.2 · Standard Therapy 3 Table 1
- Page 15 and 16:
a 1.2 · Standard Therapy 5 Table 1
- Page 17 and 18:
a 1.2 · Standard Therapy 7 tween G
- Page 19 and 20:
a 1.2 · Standard Therapy 9 Fig. 1.
- Page 21 and 22:
a 1.2 · Standard Therapy 11 of tre
- Page 23 and 24:
a 1.2 · Standard Therapy 13 Table
- Page 25 and 26:
a 1.2 · Standard Therapy 15 permit
- Page 27 and 28:
a References 17 19. Care RS, Valk P
- Page 29 and 30:
a References 19 6-thioguanine in th
- Page 31 and 32:
Acute Myeloid Leukemia: Epidemiolog
- Page 33 and 34:
a 3.1 · Epidemiology 49 3.1.4 Gend
- Page 35 and 36:
a 3.2 · Etiology 51 part of the in
- Page 37 and 38:
a 3.2 · Etiology 53 for the develo
- Page 39 and 40:
a References 55 38. Crane MM, Stom
- Page 41 and 42:
Relapsed and Refractory Acute Myelo
- Page 43 and 44:
a 4.2 · Prognostic Factors in Pati
- Page 45 and 46:
a 4.3 · Treatment of Relapsed and
- Page 47 and 48:
a 4.4 · Hematopoietic Stem Cell Tr
- Page 49 and 50:
a 4.6 · Gemtuzumab Ozogamicin 65 T
- Page 51 and 52:
a 4.7 · Relapsed and Refractory Ac
- Page 53 and 54:
a 4.7 · Relapsed and Refractory Ac
- Page 55 and 56:
a References 71 The ability of immu
- Page 57 and 58:
a References 73 39. Vogler WR, McCa
- Page 59 and 60:
a References 75 95. Sievers EL, Lar
- Page 61 and 62:
Part II - Acute Lymphoblastic Leuke
- Page 63 and 64:
78 Chapter 5 · Acute Lymphoblastic
- Page 65 and 66:
80 Chapter 5 · Acute Lymphoblastic
- Page 67 and 68:
82 Chapter 5 · Acute Lymphoblastic
- Page 69 and 70:
84 Chapter 5 · Acute Lymphoblastic
- Page 71 and 72:
86 Chapter 5 · Acute Lymphoblastic
- Page 73 and 74:
88 Chapter 5 · Acute Lymphoblastic
- Page 75 and 76:
90 Chapter 5 · Acute Lymphoblastic
- Page 77 and 78:
92 Chapter 5 · Acute Lymphoblastic
- Page 79 and 80:
Molecular Biology and Genetics Meir
- Page 81 and 82:
a 6.3 · Structural Aberrations 97
- Page 83 and 84:
a 6.3 · Structural Aberrations 99
- Page 85 and 86:
a 6.5 · Molecular Aberrations 101
- Page 87 and 88:
a References 103 clear that homozyg
- Page 89 and 90:
a References 105 53. Chim CS, Tam C
- Page 91 and 92:
a References 107 122. Lennard L, Li
- Page 93 and 94:
Diagnosis of Acute Lymphoblastic Le
- Page 95 and 96:
a 8.3 · Cytochemistry and Immunoph
- Page 97 and 98:
a 8.5 · Cytogenetic and Molecular
- Page 99 and 100:
a 8.5 · Cytogenetic and Molecular
- Page 101 and 102:
a References 127 including the reti
- Page 103 and 104:
a References 129 47. Kita K, Shirak
- Page 105 and 106:
Acute Lymphoblastic Leukemia: Clini
- Page 107 and 108:
a 7.3 · Diagnosis 111 or neoplasti
- Page 109 and 110:
a 7.3 · Diagnosis 113 Fig. 7.2. Hi
- Page 111 and 112:
a 7.3 · Diagnosis 115 The vast maj
- Page 113 and 114:
a References 117 dren: Biologic bas
- Page 115 and 116:
General Approach to the Therapy of
- Page 117 and 118:
a 9.3 · New Agents 133 dose methot
- Page 119 and 120:
a References 135 4. Gökbuget N, Ho
- Page 121 and 122:
138 Chapter 10 · Recent Clinical T
- Page 123 and 124:
140 Chapter 10 · Recent Clinical T
- Page 125 and 126:
142 Chapter 10 · Recent Clinical T
- Page 127 and 128:
144 Chapter 10 · Recent Clinical T
- Page 129 and 130:
146 Chapter 11 · Conventional Ther
- Page 131 and 132:
148 Chapter 11 · Conventional Ther
- Page 133 and 134:
150 Chapter 11 · Conventional Ther
- Page 135 and 136:
152 Chapter 11 · Conventional Ther
- Page 137 and 138:
154 Chapter 11 · Conventional Ther
- Page 139 and 140:
156 Chapter 11 · Conventional Ther
- Page 141 and 142:
158 Chapter 11 · Conventional Ther
- Page 143 and 144: ALL Therapy: Review of the MD Ander
- Page 145 and 146: a 12.2 · The Hyper-CVAD Regimen in
- Page 147 and 148: a 12.3 · Subset-Specific Approache
- Page 149 and 150: Treatment of Adult ALL According to
- Page 151 and 152: a 13.2 · Therapy for Younger (15-6
- Page 153 and 154: a 13.3 · Therapy of Ph/BCR-ABL-Pos
- Page 155 and 156: a 13.5 · Prognostic Factors 173 13
- Page 157 and 158: a References 175 Only patients with
- Page 159 and 160: Philadelphia Chromosome-Positive Ac
- Page 161 and 162: a 14.2 · Molecular Biology of the
- Page 163 and 164: a 14.3 · Treatment of Ph+ ALL 181
- Page 165 and 166: a 14.4 · Hematopoietic Stem Cell T
- Page 167 and 168: a References 185 2. Kurzrock R, Sht
- Page 169 and 170: a References 187 56. Mori T, Manabe
- Page 171 and 172: a References 189 acute lymphoblasti
- Page 173 and 174: 192 Chapter 15 · Burkitt’s Acute
- Page 175 and 176: 194 Chapter 15 · Burkitt’s Acute
- Page 177 and 178: 196 Chapter 15 · Burkitt’s Acute
- Page 179 and 180: 198 Chapter 15 · Burkitt’s Acute
- Page 181 and 182: 200 Chapter 15 · Burkitt’s Acute
- Page 183 and 184: 202 Chapter 15 · Burkitt’s Acute
- Page 185 and 186: 204 Chapter 16 · Treatment of Lymp
- Page 187 and 188: 206 Chapter 16 · Treatment of Lymp
- Page 189 and 190: 208 Chapter 16 · Treatment of Lymp
- Page 191 and 192: 210 Chapter 16 · Treatment of Lymp
- Page 193: 212 Chapter 16 · Treatment of Lymp
- Page 197 and 198: 216 Chapter 17 · The Role of Allog
- Page 199 and 200: 218 Chapter 17 · The Role of Allog
- Page 201 and 202: 220 Chapter 17 · The Role of Allog
- Page 203 and 204: 222 Chapter 17 · The Role of Allog
- Page 205 and 206: 224 Chapter 17 · The Role of Allog
- Page 207 and 208: 226 Chapter 17 · The Role of Allog
- Page 209 and 210: 228 Chapter 17 · The Role of Allog
- Page 211 and 212: 230 Chapter 18 · The Role of Autol
- Page 213 and 214: 232 Chapter 18 · The Role of Autol
- Page 215 and 216: 234 Chapter 18 · The Role of Autol
- Page 217 and 218: 236 Chapter 18 · The Role of Autol
- Page 219 and 220: 238 Chapter 19 · Novel Therapies i
- Page 221 and 222: 240 Chapter 19 · Novel Therapies i
- Page 223 and 224: 242 Chapter 19 · Novel Therapies i
- Page 225 and 226: 244 Chapter 19 · Novel Therapies i
- Page 227 and 228: 246 Chapter 19 · Novel Therapies i
- Page 229 and 230: 248 Chapter 20 · Minimal Residual
- Page 231 and 232: 250 Chapter 20 · Minimal Residual
- Page 233 and 234: 252 Chapter 20 · Minimal Residual
- Page 235 and 236: 254 Chapter 20 · Minimal Residual
- Page 237 and 238: 256 Chapter 20 · Minimal Residual
- Page 239 and 240: 258 Chapter 20 · Minimal Residual
- Page 241 and 242: 260 Chapter 20 · Minimal Residual
- Page 243 and 244: 262 Chapter 20 · Minimal Residual
- Page 245 and 246:
264 Chapter 21 · Central Nervous S
- Page 247 and 248:
266 Chapter 21 · Central Nervous S
- Page 249 and 250:
268 Chapter 21 · Central Nervous S
- Page 251 and 252:
270 Chapter 21 · Central Nervous S
- Page 253 and 254:
272 Chapter 21 · Central Nervous S
- Page 255 and 256:
274 Chapter 21 · Central Nervous S
- Page 257 and 258:
276 Chapter 22 · Relapsed Acute Ly
- Page 259 and 260:
278 Chapter 22 · Relapsed Acute Ly
- Page 261 and 262:
Emergencies in Acute Lymphoblastic
- Page 263 and 264:
a 23.5 · Hyperleukocytosis 283 LA
- Page 265 and 266:
a 23.9 · Neurological Complication
- Page 267 and 268:
a References 287 29. Hingorani AD,
- Page 269 and 270:
Subject Index A aberrant methylatio
- Page 271 and 272:
a Subject Index 291 CREB, see enhan
- Page 273 and 274:
a Subject Index 293 MUD, see matche